CCIA
ALLO icon

Campbell & Co Investment Adviser’s Allogene Therapeutics ALLO Stock Holding History

Campbell & Co Investment Adviser’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18,952
Closed -$94.2K – 918
2023
Q2 		$94.2K Buy
+18,952
New +$103K 0.02% 843

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Campbell & Co Investment Adviser's ALLO Position: Q3 2023 in Review

Campbell & Co Investment Adviser sold out of Allogene Therapeutics (ALLO) in Q3 2023, closing a stake of 18,952 shares — an estimated $94.2K sold.

Campbell & Co Investment Adviser first reported a position in ALLO in Q2 2023 and held it in 1 quarter. The position peaked at $94.2K in Q2 2023. 154 funds tracked by Wall St. Rank hold ALLO as of Q3 2023.

  • Campbell & Co Investment Adviser reported no remaining Allogene Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 18,952 Allogene Therapeutics shares in Q3 2023, an estimated $94.2K.
  • Campbell & Co Investment Adviser first reported a position in Allogene Therapeutics in Q2 2023 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Allogene Therapeutics position peaked at $94.2K in Q2 2023.
  • 154 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2023, filed 8 Nov 2023.